Hepatitis B in Children

 

 Buy Article Permissions and Reprints

ABSTRACT

Childhood hepatitis B virus (HBV) infection presents both medical and public health challenges. Infants who acquire HBV perinatally have up to 90% risk of developing chronic HBV infection. Many HBV-infected children have normal alanine aminotransferase values and minimal chronic hepatitis. Children with chronic HBV infection are usually asymptomatic but may develop chronic liver disease or hepatocellular carcinoma. Both interferon-alfa and lamivudine are available for the treatment of chronic hepatitis B in children, but the optimal treatment of children with chronic HBV infection is evolving as the indications, timing, efficacy, and side effects of the treatments are better understood. Universal infant vaccination has been shown to decrease the frequency of HBV infection and its sequelae. This article addresses aspects of HBV infection that are either unique to or different in children.

REFERENCES

• 1 Anonymous. Achievements in Public Health: hepatitis B vaccination-United States, 1982-2002.  MMWR Morb Mortal Wkly Rep . 2002;  51 549-552
  PubMedGoogle Scholar
• 2 McQuillan G M, Coleman P J, Kruszon-Moran D. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994.  Am J Public Health . 1999;  89 14-18
  PubMedGoogle Scholar
• 3 Goldstein S T, Alter M J, Williams I T. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998; implications for vaccination programs.  J Infect Dis . 2002;  185 713-719
  CrossrefPubMedGoogle Scholar
• 4 Hsu H Y, Chang M H, Chen D S, Lee C Y, Sung J L. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984; a study just before mass hepatitis B vaccination program in Taiwan.  J Med Virol . 1986;  18 301-307
  PubMedGoogle Scholar
• 5 Ni Y H, Chang M H, Huang L M. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination.  Ann Intern Med . 2001;  135 796-800
  PubMedGoogle Scholar
• 6 Barr D, Hershow R, Furner S, Handler A, Levy P. Assessing prenatal hepatitis B screening in Illinois with an inexpensive study design adaptable to other jurisdictions.  Am J Public Health . 1999;  89 19-24
  PubMedGoogle Scholar
• 7 Shiraki K. Toward control of hepatitis B in the Asia-Pacific region.  J Gastroenterol Hepatol . 2000;  15 E11-E15
  CrossrefPubMedGoogle Scholar
• 8 Lee S-D, Tsai Y-T, Wu T-C. Role of caesarean section in prevention of mother-infant transmission of hepatitis B virus.  Lancet . 1988;  2 833-834
  PubMedGoogle Scholar
• 9 Beasley R P, Stevens C E, Shiao I S, Meng H C. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B.  Lancet . 1975;  2 740-741
  PubMedGoogle Scholar
• 10 Pickering L. 2000 Red Book: Report of the Committee of Infectious Disease. Elk Grove Village, IL: American Academy of Pediatrics 2000: 98-101
  Google Scholar
• 11 Lok A S. Hepatitis B infection: pathogenesis and management.  J Hepatol . 2000;  32 89-97
  PubMedGoogle Scholar
• 12 Chu C M, Liaw Y F. Natural history of chronic hepatitis B virus infection: an immunopathological study.  J Gastroenterol Hepatol . 1997;  12 S218-S222
  PubMedGoogle Scholar
• 13 Rehermann B, Lau D, Hoofnagle J H, Chisari F V. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection.  J Clin Invest . 1996;  97 1655-1665
  PubMedGoogle Scholar
• 14 Shiraki K, Yoshihara N, Sakurai M, Eto T, Kawana T. Acute hepatitis B in infants born to carrier mother with the antibody to hepatitis B e antigen.  J Pediatr . 1980;  97 768-770
  PubMedGoogle Scholar
• 15 Kao J H, Hsu H M, Shau W Y, Chang M H, Chen D S. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan.  J Pediatr . 2001;  139 349-352
  CrossrefPubMedGoogle Scholar
• 16 Cacciola I, Cerenzia G, Pollicino T. Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection.  J Hepatol . 2002;  36 426-432
  CrossrefPubMedGoogle Scholar
• 17 Kleinknecht C, Levy M, Peix A. Membranous glomerulonephritis and hepatitis B surface antigen in children.  J Pediatr . 1979;  95 946-952
  PubMedGoogle Scholar
• 18 Southwest Pediatric Nephrology Study Group. Hepatitis B surface antigenemia in North American children with membranous glomerulonephropathy.  J Pediatr . 1985;  106 571-578
  PubMedGoogle Scholar
• 19 Lok A SF, Lai C L. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children.  Hepatology . 1988;  8 1130-1133
  CrossrefPubMedGoogle Scholar
• 20 Lok A SF, Lai C L, Su P C. Treatment of chronic hepatitis B with interferon: experience in Asian patients.  Semin Liver Dis . 1989;  9 249-253
  PubMedGoogle Scholar
• 21 Hsu H-Y, Chang M-H, Lee C-Y. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection.  Hepatology . 1992;  15 382-386
  PubMedGoogle Scholar
• 22 Bortolotti F, Cadrobbi P, Crivellaro C. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood.  Gastroenterology . 1990;  99 805-810
  PubMedGoogle Scholar
• 23 Chen P J, Chen D S. Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives.  Semin Liver Dis . 1999;  19 253-262
  PubMedGoogle Scholar
• 24 McMahon B J, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus.  Ann Intern Med . 2001;  135 759-768
  CrossrefPubMedGoogle Scholar
• 25 Tanaka T, Miyamoto H, Hino O. Primary hepatocellular carcinoma with hepatitis B virus-DNA-integration in a 4-year-old boy.  Hum Pathol . 1986;  17 202-204
  PubMedGoogle Scholar
• 26 Cheah P L, Looi L M, Lin H P, Yap S F. Childhood primary hepatocellular carcinoma and hepatitis B virus infection.  Cancer . 1990;  65 174-176
  PubMedGoogle Scholar
• 27 Giacchino R, Navone C, Facco F. HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases.  Dig Dis Sci . 1991;  36 1143-1146
  CrossrefPubMedGoogle Scholar
• 28 Pontisso P, Basso G, Perilongo G. Does hepatitis B virus play a role in primary liver cancer in children of Western countries?.  Cancer Detect Prev . 1991;  15 363-368
  PubMedGoogle Scholar
• 29 Hsu H C, Wu M Z, Chang M H, Su I J, Chen D S. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis.  J Hepatol . 1987;  5 260-267
  CrossrefPubMedGoogle Scholar
• 30 Chang M H, Chen C J, Lai M S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.  N Engl J Med . 1997;  336 1906-1907
  CrossrefPubMedGoogle Scholar
• 31 Ruíz-Moreno M, Rua M J, Molina J. Prospective, randomized trial of interferon-alpha in children with chronic hepatitis B.  Hepatology . 1991;  13 1035-1039
  CrossrefPubMedGoogle Scholar
• 32 Barbera C, Bortoletti F, Crivellaro C. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B.  Hepatology . 1994;  20 287-290
  CrossrefPubMedGoogle Scholar
• 33 Narkewicz M R, Smith D, Silverman A. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment.  J Pediatr . 1995;  127 815-818
  PubMedGoogle Scholar
• 34 Vajro P, Tedesco M, Fontanella A. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection.  Pediatr Infect Dis J . 1996;  15 223-231
  CrossrefPubMedGoogle Scholar
• 35 Sokal E M, Conjeevaram H S, Roberts E A. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.  Gastroenterology . 1998;  114 988-995
  PubMedGoogle Scholar
• 36 Lai C L, Lok A S, Lin H J. Placebo-controlled trial of recombinant alpha2-interferon in Chinese HBsAg-carrier children.  Lancet . 1987;  2 877-880
  PubMedGoogle Scholar
• 37 Lai C L, Lin H J, Lau J N. Effect of recombinant alpha2 interferon with or without prednisone in Chinese HBsAg carrier children.  Q J Med . 1991;  78 155-163
  PubMedGoogle Scholar
• 38 Sokal E M. Viral hepatitis throughout infancy to adulthood.  Acta Gastroenterol Belg . 1998;  61 170-174
  PubMedGoogle Scholar
• 39 Giacchino R, Main J, Timitilli A. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B.  Liver . 1995;  15 143-148
  PubMedGoogle Scholar
• 40 Gurakan F, Kocak N, Ozen H, Yuce A. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection.  Pediatr Infect Dis J . 2000;  19 52-56
  CrossrefPubMedGoogle Scholar
• 41 Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis.  Clin Infect Dis . 1996;  23 131-137
  PubMedGoogle Scholar
• 42 Korenman J, Baker B, Waggoner J. Long-term remission of chronic hepatitis B after alpha-interferon therapy.  Ann Intern Med . 1991;  114 629-634
  PubMedGoogle Scholar
• 43 Lin S M, Sheen I S, Chien R N, Chu C M, Liaw Y F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.  Hepatology . 1999;  29 971-975
  CrossrefPubMedGoogle Scholar
• 44 Kocak N, Gurakan F, Saltik I N, Ozen H, Yuce A. Long term prognosis of interferon nonresponder children with hepatitis B.  Am J Gastroenterol . 2000;  95 1841
  PubMedGoogle Scholar
• 45 Ruíz-Moreno M, Fernández P, Leal A. Pilot interferon-β trial in children with chronic hepatitis B who had previously not responded to interferon-alfa therapy.  Pediatrics . 1997;  99 222-225
  CrossrefPubMedGoogle Scholar
• 46 Ballauff A, Schneider T, Gerner P. Safety and efficacy of interferon retreatment in children with chronic hepatitis B.  Eur J Pediatr . 1998;  157 382-385
  CrossrefPubMedGoogle Scholar
• 47 Iorio R, Pensati P, Botta S. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis.  Pediatr Infect Dis J . 1997;  16 984-990
  CrossrefPubMedGoogle Scholar
• 48 Gottrand F, Michaud L, Guimber D. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis.  Eur J Pediatr . 1996;  155 1031-1034
  CrossrefPubMedGoogle Scholar
• 49 Comanor L, Minor J, Conjeevaram H S. Impact of chronic hepatitis B and interferon-alfa therapy on growth of children.  J Viral Hepat . 2001;  8 139-147
  CrossrefPubMedGoogle Scholar
• 50 Lai C-L, Chien R-N, Leung N WY. A one-year trial of lamivudine for chronic hepatitis B.  N Engl J Med . 1998;  339 61-68
  CrossrefPubMedGoogle Scholar
• 51 Dienstag J L, Schiff E R, Wright T L. Lamivudine as initial treatment for chronic hepatitis B in the United States.  N Engl J Med . 1999;  341 1256-1263
  CrossrefPubMedGoogle Scholar
• 52 Liaw Y-F, Leung N WY, Chang T-T. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.  Gastroenterology . 2000;  119 172-180
  CrossrefPubMedGoogle Scholar
• 53 Leung N W, Lai C L, Chang T T. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.  Hepatology . 2001;  33 1527-1532
  CrossrefPubMedGoogle Scholar
• 54 Jonas M M, Kelley D A, Mizerski J. Clinical trial of lamivudine in children with chronic hepatitis B.  N Engl J Med . 2002;  346 1706-1713
  CrossrefPubMedGoogle Scholar
• 55 Dikici B, Bosnak M, Kara I H. Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection.  Pediatr Infect Dis J . 2001;  20 988-992
  PubMedGoogle Scholar
• 56 Smith N, Yusuf H, Averhoff F. Surveillance and prevention of hepatitis B virus transmission.  Am J Public Health . 1999;  89 11-13
  PubMedGoogle Scholar
• 57 Yuen M F, Lim W L, Cheng C C, Lam S K, Lai C L. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children.  Hepatology . 1999;  29 924-927
  CrossrefPubMedGoogle Scholar
• 58 Szmuness W, Stevens C E, Harley E J. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.  N Engl J Med . 1980;  303 833-841
  PubMedGoogle Scholar
• 59 Anonymous. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Morb Mortal Wkly Rep . 1996;  45 1-35
  PubMedGoogle Scholar
• 60 Ascherio A, Zhang S M, Hernan M A. Hepatitis B vaccination and the risk of multiple sclerosis.  N Engl J Med . 2001;  344 327-332
  CrossrefPubMedGoogle Scholar
• 61 Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group.  N Engl J Med . 2001;  344 319-326
  CrossrefPubMedGoogle Scholar
• 62 Giacchino R, Main J, Timitilli A. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B.  Liver . 1995;  15 143-148
  PubMedGoogle Scholar